Teva (NYSE:TEVA) continues to prepare for the introduction of fremanezumab, for the treatment of chronic migraine, despite disappointing results in some recent studies. …
Warren Buffett is Betting Big on AAPL and TEVA.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares are climbing nearly 9% in Thursday’s trading session, after Warren Buffett’s Berkshire disclosed a $350 million brand …
BTIG’s Tim Chiang is out with a bearish case against Teva after last week’s less-than-stellar 2018 guidance reveal.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) today announced the US launch of its generic equivalents to Valeant’s (NYSE:VRX) 30-year-old drug, Syprine (trientine hydrochloride), used …
As Wall Street scrambles away from Teva after a sharp guidance miss for 2018, Oppenheimer’s Derek Archila shares his two (cautious) cents.
Generics price erosion; the ghost of debt maturation- BTIG’s Tim Chiang sees too many risks to hope for Teva’s recovery anymore.
Though Guggenheim’s Rohit Vanjani is not surprised by Teva’s amendment of financial leverage covenants, he sees this as a “watch” item.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced today it has completed the sale of a portfolio of products within its global women’s health …
BTIG’s Tim Chiang cautions that Momenta’s generic 40mg Copaxone is not the only rival coming for Teva.
